FDA approves sofosbuvir, ushering in paradigm shift in HCV treatment

|By:, SA News Editor

The FDA approves Gilead's (GILD) sofosbuvir for HCV.

One FDA official calls this "a significant shift in the treatment paradigm for some patients with chronic HCV" — this is the first HCV treatment to exhibit both safety and efficacy without the need for concurrent interferon treatment. (PR)